News
Instil Bio (TIL) Upgraded to Buy: What Does It Mean for the Stock?
Instil Bio, Inc. (TIL) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces
What Makes Ares Commercial Real Estate (ACRE) a New Strong Buy Stock
Ares Commercial Real Estate (ACRE) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most
Freightos Limited (CRGO) Upgraded to Buy: Here's What You Should Know
Freightos Limited (CRGO) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces
Wolters Kluwer (WTKWY) Upgraded to Strong Buy: Here's Why
Investors might want to bet on Wolters Kluwer NV (WTKWY), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates
All You Need to Know About Pacific Biosciences (PACB) Rating Upgrade to Buy
Pacific Biosciences of California (PACB) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most
Werewolf Therapeutics (HOWL) Upgraded to Buy: Here's What You Should Know
Investors might want to bet on Werewolf Therapeutics, Inc. (HOWL), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates
Midland States Bancorp (MSBI) Upgraded to Buy: Here's What You Should Know
Midland States Bancorp (MSBI) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates
All You Need to Know About Globale Online (GLBE) Rating Upgrade to Buy
Investors might want to bet on Global-e Online Ltd. (GLBE), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is
All You Need to Know About Eastern Bankshares (EBC) Rating Upgrade to Strong Buy
Eastern Bankshares, Inc. (EBC) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces
Clearside Biomedical (CLSD) Upgraded to Buy: Here's What You Should Know
Clearside Biomedical, Inc. (CLSD) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates
Are You Looking for a Top Momentum Pick? Why Astronics Corporation (ATRO) is a Great Choice
Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell
D-Wave Quantum Inc. (QBTS) Is Up 53.47% in One Week: What You Should Know
Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell
What Makes CuriosityStream Inc. (CURI) a Strong Momentum Stock: Buy Now?
Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even
Here's Why Maplebear (CART) is a Great Momentum Stock to Buy
Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even
Are You Looking for a Top Momentum Pick? Why UniCredit S.p.A. Unsponsored ADR (UNCRY) is a Great Choice
Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell
Here Are the Top-Performing Stocks From the S&P 500 This Year
The stock market has been one heck of a seesaw in 2025.
A bit over a month ago, the S&P 500 was down more than 15% on the year and narrowly avoided an official bear market (in fact, it closed down
3 Key Reasons to Buy Fortinet Stock Beyond its 11% Year-to-Date Rise
Fortinet FTNT shares have gained 10.6% in the year-to-date (YTD) period, outperforming the Zacks Computer and Technology sector and the S&P 500 index’s decline of 1.7% and 0.4%, respectively.FTNT’s
ORIC Stock Surges on Upbeat Initial Data From Prostate Cancer Study
Shares of ORIC Pharmaceuticals ORIC surged more than 20% in the pre-market hours today after announcing potentially best-in-class preliminary efficacy and safety data from the ongoing early-stage
Top 3D Printing Stocks to Add to Your Portfolio for Impressive Returns
An updated edition of the April 08, 2025 article.
3D Printing, or additive manufacturing, is the process of transforming digital designs into physical objects by building them layer by layer with
Coca-Cola Stock Has Momentum, PepsiCo May Be the Better Buy
The stocks of The Coca-Cola Company (NYSE: KO) and PepsiCo. Inc. (NASDAQ: PEP) are a source of debate between value and growth investors. In 2025, KO stock clearly holds the upper hand. The stock
Okta Declines 16% Post Q1 Earnings: Buy, Sell or Hold the Stock?
Okta OKTA shares dropped 16.16% on Wednesday to close at $105.22 following first-quarter fiscal 2026 results on Tuesday. Although the company reported impressive earnings and revenue growth, the
HNI (HNI) Could Be a Great Choice
Whether it's through stocks, bonds, ETFs, or other types of securities, all investors love seeing their portfolios score big returns. However, when you're an income investor, your primary focus is
Are You Looking for a High-Growth Dividend Stock?
Whether it's through stocks, bonds, ETFs, or other types of securities, all investors love seeing their portfolios score big returns. However, when you're an income investor, your primary focus is
BMY's Opdivo SC Gets EU Nod for Multiple Solid Tumor Indications
Bristol Myers BMY announced that the European Commission (EC) has approved the subcutaneous formulation of Opdivo (nivolumab) across multiple solid tumor indications. The decision applies to all 27


